These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24237295)

  • 1. Comparative effectiveness research and measuring the level of pharmaceutical innovation in the EU.
    Annemans L; Cleemput I; Hulstaert F; Simoens S
    J Comp Eff Res; 2012 Jan; 1(1):19-29. PubMed ID: 24237295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New safe medicines faster: A proposal for a key action within the European union's 6th framework programme.
    Bjerrum OJ
    Pharmacol Toxicol; 2000; 86 Suppl 1():23-6. PubMed ID: 10905750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to revive breakthrough innovation in the pharmaceutical industry.
    Munos BH; Chin WW
    Sci Transl Med; 2011 Jun; 3(89):89cm16. PubMed ID: 21715677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current challenges for the pharmaceutical research industry].
    Chalchat B
    Ann Pharm Fr; 1993; 51(1):16-25. PubMed ID: 8215118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can open-source drug R&D repower pharmaceutical innovation?
    Munos B
    Clin Pharmacol Ther; 2010 May; 87(5):534-6. PubMed ID: 20407458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The innovative medicines initiative: a European response to the innovation challenge.
    Goldman M
    Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whatever happened to the Norwegian Medical Need Clause? Lessons for current debates in EU pharmaceutical regulation.
    Brooks E; Geyer R
    Sociol Health Illn; 2016 May; 38(4):576-91. PubMed ID: 26564268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Policy making on data exclusivity in the European Union: from industrial interests to legal realities.
    Adamini S; Maarse H; Versluis E; Light DW
    J Health Polit Policy Law; 2009 Dec; 34(6):979-1010. PubMed ID: 20018988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valorising and creating access to innovative medicines in the European union.
    Annemans L; Cleemput I; Hulstaert F; Simoens S
    Front Pharmacol; 2011; 2():57. PubMed ID: 22013421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving pharmaceutical innovation by building a more comprehensive database on drug development and use.
    Daniel GW; Cazé A; Romine MH; Audibert C; Leff JS; McClellan MB
    Health Aff (Millwood); 2015 Feb; 34(2):319-27. PubMed ID: 25646113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can a medical need clause help manage the growing costs of prescription drugs in the EU?
    Brooks E; Geyer R
    Health Econ Policy Law; 2016 Apr; 11(2):179-92. PubMed ID: 26333920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and Pharmaceutical Solutions through Analysis (CPSA BRASIL 2015): on the way to innovation - pharmaceutical/analytical technology, regulation and knowledge management.
    Needham S; Yates N; Barrientos R; Steel M; Lee M
    Bioanalysis; 2015 Dec; 7(23):2977-9. PubMed ID: 26617112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New strategies for innovation in global health: a pharmaceutical industry perspective.
    Witty A
    Health Aff (Millwood); 2011 Jan; 30(1):118-26. PubMed ID: 21209447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health technology assessment and comparative effectiveness research: a pharmaceutical industry perspective.
    Hao Y; Thomas A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):447-54. PubMed ID: 23977973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European perspectives on pediatric formulations.
    Breitkreutz J
    Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Keynote review: Is declining innovation in the pharmaceutical industry a myth?
    Schmid EF; Smith DA
    Drug Discov Today; 2005 Aug; 10(15):1031-9. PubMed ID: 16055019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug discovery in pharmaceutical industry: productivity challenges and trends.
    Khanna I
    Drug Discov Today; 2012 Oct; 17(19-20):1088-102. PubMed ID: 22627006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The socio-political roots of pharmaceutical uncertainty in the evaluation of 'innovative' diabetes drugs in the European Union and the US.
    Davis C; Abraham J
    Soc Sci Med; 2011 May; 72(9):1574-81. PubMed ID: 21474222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The European Union and drugs].
    Viala G; Campion MD
    Ann Pharm Fr; 1995; 53(4):184-7. PubMed ID: 7574273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.